Promacta

Approved Uses

Promacta is used to treat several conditions involving low blood platelet counts (thrombocytopenia) or bone marrow failure. These include:

• Chronic Immune Thrombocytopenia (ITP): This medication is used for adults and children 1 year of age and older with ITP when other treatments, such as corticosteroids or surgery to remove the spleen, have not worked well enough.
• Severe Aplastic Anemia (SAA): Promacta is used in adults and children 2 years of age and older with SAA. It may be used as a first-line treatment alongside other medications or as a stand-alone treatment when other therapies have failed.
• Chronic Hepatitis C: It is used to increase platelet counts in patients with chronic hepatitis C so they can begin and maintain interferon-based antiviral therapy.

The primary goal of using Promacta is to raise platelet levels enough to lower the risk of bleeding, rather than to achieve a normal platelet count.

Mechanism of Action

Promacta belongs to a class of medications called thrombopoietin (TPO) receptor agonists. It works by targeting the same receptors as thrombopoietin, a natural hormone in the body responsible for regulating the production of platelets.

Platelets are small blood cells that help the blood clot. When Promacta binds to specific receptors on the surface of cells in the bone marrow, it triggers a process that increases the number of platelets in the bloodstream. This process involves:

• Cell Stimulation: The medication signals the bone marrow to produce more megakaryocytes, which are the large cells that eventually become platelets.
• Growth and Maturation: It encourages these precursor cells to grow and mature more effectively.
• Increased Production: As these cells mature, they release more platelets into circulation.

By stimulating the bone marrow to produce more platelets, Promacta helps reduce the risk of bruising and bleeding in patients with conditions such as chronic immune thrombocytopenia (ITP), severe aplastic anemia, or low platelet counts associated with chronic hepatitis C.

Common Side Effects

Many people using Promacta experience mild side effects. These may include:

• Nausea or diarrhea
• Headache
• Muscle aches or back pain
• Tiredness or weakness
• Cough or flu-like symptoms
• Tingling or numbness in the hands or feet
• Skin rash or hair loss

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact a healthcare provider if you experience:

• Liver problems: Yellowing of the skin or eyes (jaundice), dark-colored urine, or pain in the upper right side of the stomach area.
• Blood clots: Swelling, pain, or tenderness in one leg; sudden shortness of breath; or chest pain.
• Vision changes: Blurred vision or other changes in sight, as this medication may increase the risk of developing cataracts.
• Severe allergic reactions: Swelling of the face, lips, or tongue; difficulty breathing; or a severe rash.

In children, common side effects often include symptoms of a cold or upper respiratory tract infection, such as a sore throat or runny nose.

Liver Toxicity

Promacta has a boxed warning because it may cause serious liver damage. Healthcare providers typically perform blood tests to check liver function before starting the medication and at regular intervals during treatment. Signs of liver problems may include:

• Yellowing of the skin or the whites of the eyes (jaundice).
• Unusually dark urine.
• Pain in the upper right stomach area or extreme tiredness.

Risk of Blood Clots

Taking this medication can increase the risk of developing blood clots in the veins or arteries, even if platelet counts are within the normal range. These clots may occur in the lungs, legs, or the blood vessels leading to the liver. The risk is higher for individuals with chronic liver disease or those with known risk factors for blood clots.

Progression of Bone Marrow Disorders

In patients with myelodysplastic syndromes (MDS), Promacta may increase the risk of the condition progressing to acute myeloid leukemia (AML). This medication is not approved for the treatment of MDS.

Cataracts

New or worsening cataracts (clouding of the lens of the eye) have been reported in people taking Promacta. Routine eye examinations may be recommended before and during treatment to monitor for changes in vision.

Bone Marrow Changes

Promacta may cause changes in the bone marrow, such as the development of reticulin fibers. These changes are usually monitored through regular blood cell counts and, in some cases, bone marrow biopsies to ensure the marrow is functioning correctly.

Bleeding Risk After Stopping

When treatment with Promacta is stopped, platelet counts may drop to levels lower than they were before starting the medication. This can increase the risk of serious bleeding for several weeks after the last dose. Healthcare providers usually monitor blood counts for at least four weeks after the medication is discontinued.

Pregnancy

Data regarding the use of Promacta during pregnancy is limited. Animal studies have shown that the drug may cause fetal harm, including decreased birth weight and minor skeletal changes. Due to these potential risks, the medication is generally only used during pregnancy if the potential benefit to the patient outweighs the potential risk to the fetus.

Healthcare providers may require a pregnancy test before starting treatment. Individuals who can become pregnant are typically advised to use effective birth control while taking Promacta and for at least two weeks after the final dose. If you suspect you are pregnant while taking this medication, notify your doctor immediately.

Breastfeeding

It is not known if Promacta passes into human breast milk or if it has any effect on a nursing infant or milk production. Because of the potential for serious side effects in a breastfed child, breastfeeding is not recommended during treatment. Patients should discuss alternative infant feeding options with their healthcare provider.

Available Forms

Promacta is supplied in the following oral formulations:

• Oral Tablets: These are film-coated tablets intended to be swallowed whole.
• For Oral Suspension: This is a powder provided in packets. It must be mixed with water to create a liquid suspension before it is taken.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved Promacta for several specific conditions:

• Chronic Immune Thrombocytopenia (ITP): For adults and children 1 year and older when other treatments or surgery have not worked well enough.
• Chronic Hepatitis C: To treat low blood platelet counts in patients so they can start and maintain interferon-based therapy.
• Severe Aplastic Anemia: For use as a first-line treatment in combination with other therapies or when other medicines have failed.

Boxed Warning

Promacta carries a boxed warning, the FDA’s most serious type of warning, regarding hepatotoxicity (liver toxicity). The medication can cause serious and potentially life-threatening liver injury. Healthcare providers are required to perform liver function tests before starting treatment and monitor them regularly throughout therapy.

Regulatory History and Safety Monitoring

The FDA previously required a Risk Evaluation and Mitigation Strategy (REMS) for Promacta to manage its risks, but this requirement was later removed as the agency determined the drug's benefits could be managed through standard labeling and monitoring. However, the drug remains under close regulatory oversight. Patients must receive a Medication Guide explaining the risks of liver damage and blood clots (thrombotic complications). Regulatory authorities also monitor for potential risks related to cataracts and the development of abnormal blood cells.

Insurance and Coverage

Promacta is a specialty medication, and most insurance plans, including Medicare and private insurance, provide coverage for it. However, because it is often classified as a specialty drug, it may be placed on a high-cost tier, which can result in significant out-of-pocket expenses or require prior authorization from a healthcare provider.

Financial Assistance

Patients may be able to reduce their costs through various programs:

• Co-pay Cards: Eligible patients with commercial insurance may qualify for manufacturer-sponsored co-pay cards that lower the cost of prescriptions.
• Patient Assistance Programs: For those without insurance or with limited coverage, the manufacturer often provides assistance programs based on financial need.
• Specialty Pharmacies: This medication is typically dispensed through specialty pharmacies, which can often help patients navigate insurance requirements and find financial support options.

The total price will also depend on whether the medication is prescribed as a tablet or an oral suspension and the specific dosage strength required for the condition being treated.